UNLABELLED: Endothelial monocyte-activating polypeptide-II (EMAP-II) is a novel proinflammatory cytokine with anti-angiogenic properties. The aim of this work was to evaluate in vivo antitumor activity of EMAP-II in growing human prostate adenocarcinoma xenograft mouse model. MATERIALS AND METHODS: Recombinant human EMAP-II was expressed in Escherichia coli and purified after cleavage with enterokinase (EMAP-II e). EMAP-II preparations were injected to CBA mice bearing subrenal capsule xenografts of human prostate adenocarcinoma. After 3-days treatment, the xenografts were isolated and weighed, then the transplants exposed to EMAP II e (100 or 200 microg/kg b. w.) were examined histologically. RESULTS: EMAP-II administered daily at a dose of 100 or 200 microg/kg b. w. caused striking retardation of local tumor progression as compared to the controls. Low dose (10 microg/kg) was effective in some cases. CONCLUSION: EMAP II exhibits significant antitumor activity in vivo in human prostate adenocarcinoma xenografts in mouse model.
UNLABELLED: Endothelial monocyte-activating polypeptide-II (EMAP-II) is a novel proinflammatory cytokine with anti-angiogenic properties. The aim of this work was to evaluate in vivo antitumor activity of EMAP-II in growing humanprostate adenocarcinoma xenograft mouse model. MATERIALS AND METHODS: Recombinant humanEMAP-II was expressed in Escherichia coli and purified after cleavage with enterokinase (EMAP-II e). EMAP-II preparations were injected to CBA mice bearing subrenal capsule xenografts of humanprostate adenocarcinoma. After 3-days treatment, the xenografts were isolated and weighed, then the transplants exposed to EMAP II e (100 or 200 microg/kg b. w.) were examined histologically. RESULTS:EMAP-II administered daily at a dose of 100 or 200 microg/kg b. w. caused striking retardation of local tumor progression as compared to the controls. Low dose (10 microg/kg) was effective in some cases. CONCLUSION:EMAP II exhibits significant antitumor activity in vivo in humanprostate adenocarcinoma xenografts in mouse model.
Authors: Martha Stathaki; Athanasios Armakolas; Andreas Dimakakos; Loukas Kaklamanis; Ioannis Vlachos; Manoussos M Konstantoulakis; George Zografos; Michael Koutsilieris Journal: Mol Med Date: 2014-03-18 Impact factor: 6.354
Authors: Chujun Yuan; Lin Yan; Pallavi Solanki; Stephen F Vatner; Dorothy E Vatner; Margaret A Schwarz Journal: J Mol Cell Cardiol Date: 2014-11-29 Impact factor: 5.000
Authors: Daniel D Lee; Charitharth V Lal; Elizabeth A Persad; Chinn-Woan Lowe; Anna M Schwarz; Niranjan Awasthi; Roderich E Schwarz; Margaret A Schwarz Journal: Am J Respir Cell Mol Biol Date: 2016-10 Impact factor: 6.914